New data from NanoBio's nanoemulsion-based adjuvant platform to be presented

Dec 8 2009

NanoBio Corporation announced today that its CEO and Founder, James R. Baker, Jr., M.D., will present new data from studies of its nanoemulsion-based adjuvant platform during the World Influenza Congress, taking place from December 7-9, 2009 in Brussels, Belgium. The presentation details are as follows:

Dr. Baker will discuss the mechanisms of action and key characteristics of intranasal nanoemulsion-adjuvanted vaccines, and will share additional data demonstrating:

• The nanoemulsion adjuvant’s uptake into dendritic cells and generation of Th1-biased immunity without inducing an inflammatory response;
• The efficacy of nanoemulsion-adjuvanted intranasal influenza vaccines in ferret models;
• The efficacy of nanoemulsion-based adjuvants in subcutaneous and intramuscular models;
• The safety results from NanoBio’s ongoing Phase 1 clinical study of NB-1008, a nanoemulsion-adjuvanted seasonal influenza vaccine administered by nasal dropper.

Dr. Baker will also be a featured speaker in a panel session titled, “How can we develop strategies to maximize chances of approval for novel adjuvants?” on Wednesday, Dec. 9 at 11:30 a.m.